Characteristic | Overall | Worsening | PRMS | SPMS |
---|---|---|---|---|
 |  | RRMS |  |  |
At baseline | Â | Â | Â | Â |
 Patients enrolled,a n (%) | 509 (100.0) | 81 (15.9) | 33 (6.5) | 395 (77.6) |
 Mean age, years (range) | 46 (19–68) | 40 (19–63) | 47 (30–64) | 47 (25–68) |
 Women,% | 67.6 | 77.8 | 54.5 | 66.6 |
 White,% | 88.6 | 85.2 | 87.9 | 89.4 |
 History of MS, n | 506 | 80 | 32 | 394 |
  Median EDSS score (range) | 6.0 (0.0–9.0) | 4 (1.0–8.0) | 6.0 (1.5–8.5) | 6.5 (0.0–9.0) |
  Median years since onset (range) | 11.8 (0.4–45.3) | 8.0 (0.4–29.2) | 11.5 (0.6–34.5) | 13.0 (0.6–45.3) |
  Median years since diagnosis (range) | 8.6 (0.0–39.9) | 4.8 (0.0–24.6) | 7.3 (0.1–26.5) | 9.3 (0.1–39.9) |
  Median years since most recent relapse (range) | 0.4 (0.0–20.3) | 0.2 (0.0–2.4) | 0.2 (0.0–4.6) | 0.5 (0.0–20.3) |
  Patients with no prior treatment for MS, n (%) | 16 (3.1) | 3 (3.7) | 2 (6.1) | 11 (2.8) |
  Women with regular menses, n (%) | 128 (37.2) | 34 (54.0) | 7 (38.9) | 87 (33.1) |
 Cardiac, n | 505 | 81 | 32 | 392 |
  Mean LVEF,% (range) | 62 (50–83) | 62 (50–83) | 63 (52–79) | 62 (50–83) |
Study completion, n | 509 | 81 | 33 | 395 |
 Patients who did not complete | 486 (95.5) | 74 (91.4) | 32 (97.0) | 380 (96.2) |
 Mitoxantrone treatment,b n (%) |  |  |  |  |
  Did not complete 5-year study,c n (%) | 320 (62.9) | 46 (56.8) | 27 (81.8) | 247 (62.5) |
  Completed 5-year study,c n (%) | 166 (32.6) | 28 (34.6) | 5 (15.2) | 133 (33.7) |
 Patients who completed | 23 (4.5) | 7 (8.6) | 1 (3.0) | 15 (3.8) |
 Mitoxantrone treatment,b n (%) | ||||
  Did not complete 5-year study,c n (%) | 17 (3.3) | 5 (6.2) | 1 (3.0) | 11 (2.8) |
  Completed 5-year study,c n (%) | 6 (1.2) | 2 (2.5) | 0 (0) | 4 (1.0) |